Answers are grounded in this paper and cite their sources.
Purpose: To evaluate the 12-month efficacy and safety of intravitreal Dobesilate in dry age-related macular degeneration (ARMD). Patients and Methods: Thirty patients with visual impairment due to dry ARMD received a single intravitreal injection of Dobesilate in the study eye. Ophthalmic evaluation included fundoscopy, spectral-domain optical coherence tomography (SD-OCT) and best-corrected visual acuity (BCVA) prior to therapy and 1 week, 1 and 12-months after treatment. Main Outcome Measures: Mean change in BCVA. Retinal anatomy. Incidence of ocular and non-ocular adverse events. Results: There was a statistically significant increase in mean BCVA at 12 months compared with baseline (0.30±0.04 vs. 0.49±0.06 SEM) (p<0.001). BCVA increased in 26 of 30 eyes (86.7%) and only 4 eyes (13.3%) didn’t show any change. Intravitreal Dobesilate injection resulted in a significant improvement of outer retinal anatomy. Visual improvement was not correlated with age. No ocular or systemic events were reported during the follow-up period. Conclusions: This study confirms the safety of Dobesilate intravitreally injected, as well as the improvement in visual acuity and retinal anatomy at 12 months follow-up. Intravitreal Dobesilate may be a promising therapeutic strategy targeting the inflammatory component of dry ARMD.
No takes yet. Share an insight, caveat, or question.
Cuevas et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: